Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Senhwa BiosciencesROCO:6492 -1.35%70 Current Ratio is 17.21 as of Dec. 2025, which is 43% below its 10-year median of 30.06. GuruFocus rates ROCO:6492 with a GF Score™ of 70/100 and a GF Value™ of NT$46.74 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,411 Biotechnology companies, Senhwa Biosciences ranks better than 89.44% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Senhwa Biosciences's current ratio for the quarter that ended in Dec. 2025 was 17.21.
Senhwa Biosciences has a current ratio of 17.21. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Senhwa Biosciences's Current Ratio or its related term are showing as below:
ROCO:6492'
s Current Ratio Range Over the Past 10 Years
Min: 17.21 Med: 30.06 Max: 49.69
Current: 17.21
During the past 13 years, Senhwa Biosciences's highest Current Ratio was 49.69. The lowest was 17.21. And the median was 30.06.
ROCO:6492's Current Ratio is ranked better than 89.44% of 1411
companies
in the Biotechnology industry
Industry Median: 3.88
vs ROCO:6492: 17.21
Senhwa Biosciences (ROCO:6492) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Senhwa Biosciences Current Ratio Related Terms
Senhwa Biosciences Current Ratio Historical Data
* Premium members only.
The historical data trend for Senhwa Biosciences's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6492 vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Senhwa Biosciences's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Senhwa Biosciences Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Senhwa Biosciences's Current Ratio distribution charts can be found below:
* The bar in red indicates where Senhwa Biosciences's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Senhwa Biosciences (ROCO:6492) has a Current Ratio of 17.21 as of Dec. 2025. This is 43% below median its historical median of 30.06. Over the past decade, Senhwa Biosciences' Current Ratio has ranged from 17.21 to 49.69. According to the industry distribution chart, Senhwa Biosciences ranks #149 out of 1411 companies in the Biotechnology industry, placing it in the top 10.6%.
Is Senhwa Biosciences' Current Ratio too high?
Senhwa Biosciences' current Current Ratio of 17.21 is 43% below median its 10-year median of 30.06. Over the past 10 years, this metric has ranged from a low of 17.21 to a high of 49.69. The Biotechnology industry median Current Ratio is 3.88. Senhwa Biosciences' value of 17.21 is 343.6% above this industry median. Based on the distribution chart, Senhwa Biosciences ranks #149 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Senhwa Biosciences has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Senhwa Biosciences' Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Senhwa Biosciences ranks #149 out of 1411 companies for Current Ratio. This places Senhwa Biosciences in the top 11% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.88. Senhwa Biosciences' value of 17.21 is 343.6% above this benchmark. Historically, Senhwa Biosciences' own Current Ratio has ranged from 17.21 to 49.69 over the past decade. While the company's 10-year median is 30.06 vs. the industry median of 3.88, Senhwa Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.88, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Senhwa Biosciences's current Current Ratio of 17.21 is 343.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Senhwa Biosciences's current Current Ratio is 17.21, which is 43% below median its own 10-year median of 30.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senhwa Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Senhwa Biosciences (ROCO:6492) is currently considered Fairly Valued. The stock's GF Value™ is NT$46.74, compared to a current price of NT$43.70 — trading 6.5% below its estimated fair value. The current Current Ratio is 17.21, which is 43% below median its 10-year median of 30.06 and 343.6% above the Biotechnology industry median of 3.88. Senhwa Biosciences' overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Senhwa Biosciences (ROCO:6492), the current Current Ratio is 17.21 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Senhwa Biosciences (ROCO:6492) Overvalued in 2026?
Based on GuruFocus' analysis, Senhwa Biosciences stock appears to be undervalued.
The current stock price of NT$43.70 is trading 6.5% below its estimated GF Value™ of NT$46.74.
GuruFocus considers Senhwa Biosciences to be Fairly Valued.
Key valuation signals for ROCO:6492:
Current Ratio: 17.21 (43% below median its 10-year median of 30.06)
GF Value™: NT$46.74 vs. price of NT$43.70 (6.5% below fair value)
Industry Position: 343.6% above the Biotechnology median (#149 of 1411)
No single metric tells the full story. See the ROCO:6492 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Senhwa Biosciences Inc is engaged in the development of new drugs and special pharmaceutical ingredients, focusing on human efficacy. The company's product pipeline includes Pidnarulex (CX-5461), being developed as a therapy for solid tumours, B-cell lymphoma, ovarian cancer, and other oncology indications; and Silmitasertib (CX-4945), being developed to counter neuroblastoma, medulloblastoma, basal cell carcinoma, and other indications. Geographically, the company generates all of its revenue from Taiwan.
70GF Score
Get the complete analysis for ROCO:6492
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6492 has been successfully added to your 
